3/3
02:15 pm
nuvb
Rating for NUVB
Low
Report
Rating for NUVB
3/3
10:42 am
nuvb
Rating for NUVB
Medium
Report
Rating for NUVB
3/3
10:42 am
nuvb
Rating for NUVB
Medium
Report
Rating for NUVB
2/10
09:41 am
nuvb
Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
2/10
09:41 am
nuvb
Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
2/10
09:36 am
nuvb
Rating for NUVB
Low
Report
Rating for NUVB
2/10
09:36 am
nuvb
Rating for NUVB
Low
Report
Rating for NUVB
1/21
09:38 am
nuvb
Rating for NUVB
Low
Report
Rating for NUVB
1/21
09:38 am
nuvb
Rating for NUVB
Low
Report
Rating for NUVB
1/21
07:17 am
nuvb
Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/21
07:17 am
nuvb
Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/9
06:10 am
nuvb
Nuvation Bio (NYSE:NUVB) was upgraded by analysts at UBS Group AG to a "hold" rating.
Medium
Report
Nuvation Bio (NYSE:NUVB) was upgraded by analysts at UBS Group AG to a "hold" rating.
1/7
03:23 pm
nuvb
Rating for NUVB
Low
Report
Rating for NUVB
1/7
08:20 am
nuvb
Nuvation Bio initiated with a Neutral at UBS
Medium
Report
Nuvation Bio initiated with a Neutral at UBS
1/7
02:01 am
nuvb
Nuvation Bio (NYSE:NUVB) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
Medium
Report
Nuvation Bio (NYSE:NUVB) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.